David Ting, MD

David Ting, MD is the Scientific Co-Founder of PanTher Therapeutics.

As a physician-scientist, cancer biologist, and bioengineer, David is currently Associate Clinical Director for Innovation, Co-Director Biomarker Discovery Lab, and a gastrointestinal oncologist at the Massachusetts General Hospital Cancer Center. He is also currently Associate Professor of Medicine at Harvard Medical School.

Prior to PanTher Therapeutics, David performed biomedical research under Dr. Robert Langer working on DNA vaccine delivery systems, and then a Howard Hughes Medical Institute fellowship at the Whitehead Institute at MIT working on stem cell biology with Dr. George Daley. David also co-founded TellBio, Inc. and ROME Therapeutics.

David holds an MD from Harvard Medical School from the Harvard-MIT Health Sciences and Technology program and a BS in both Chemical Engineering and Biology from MIT.

Elazer Edelman, MD, PhD

Elazer Edelman, MD, PhD is the Scientific Co-Founder of PanTher Therapeutics. In addition to his role at PanTher, Elazer is the Edward J. Poitras Professor in Medical Engineering and Science at MIT, Professor of Medicine at Harvard Medical School, and Senior Attending Physician in the coronary care unit at the Brigham and Women’s Hospital.

Key Opinion Leader in local drug delivery and implantable devices, Elazer serves as an advisor for the FDA and several companies in the medical device industry and has been instrumental in propelling several multiple devices from conceptualization to clinical realization. He also directs MIT’s Institute for Medical Engineering and Science (IMES) and Clinical Research Center (CRC) as well as the Harvard-MIT Biomedical Engineering Center (BMEC) – all dedicated to applying the rigors of the physical sciences to elucidate fundamental biologic processes and mechanisms of disease.

Elazer holds an MD from Harvard Medical School, PhD in Medical Engineering and Medical Physics from MIT, MS degree in Electrical Engineering and Computer Sciences from MIT, and BS in Bioelectrical Engineering and in Applied Biology from MIT.

Meg Lashof-Sullivan, PhD

Meg Lashof-Sullivan, PhD is Director of R&D at PanTher Therapeutics. As a biomedical engineer with a background in biomaterials, Meg has expertise in polymer synthesis, drug delivery, and analytical laboratory techniques. She has led the transfer of PanTher’s PTM-101 from the academic laboratory to a clinical manufacturing process. She developed the in-house testing methods used to characterize the PTM-101 prototype and has overseen the external pre-clinical studies necessary to bring PTM-101 to the clinic.

Prior to joining PanTher Therapeutics, Meg completed her postdoctoral fellowship at The Henry M. Jackson Foundation for the Advancement of Military Medicine at the Naval Medical Research Center’s NeuroTrauma department. Before that,she served as a General Engineer at the U.S. Department of Energy.

Meg holds a PhD in Biomedical Engineering from Case Western Reserve University and both a BE in Engineering and BA in Biology and Engineering from Dartmouth College.

Sara Fanning

Sara Fanning is the Director of Business Operations at PanTher Therapeutics. As a business operation professional, Sara has deep experience in developing and implementing strategic projects, processes, and systems critical to company success. 

Prior to joining PanTher Therapeutics, Sara served as Director of Project Management at Evolved By Nature, where she oversaw the sustainable chemicals business unit. Before that, she served as Site Operations Manager at Bio-Rad Laboratories (formerly GnuBIO) and Manager of Administration and Operations at Brigham and Women’s Hospital. 

Sara holds a BS degree in Biological Sciences from the University of Nebraska.

Chris Johnson, PhD

Chris Johnson, PhD is a R&D Scientist at PanTher Therapeutics. He is a biomedical engineer with a background in polymer biomaterials for drug delivery. Chris has expertise in polymer scaffold development, drug delivery, and analytical laboratory techniques.

Prior to joining PanTher Therapeutics, Chris was an Immunology Research Scientist at Bio-Techne where he led the team further developing the NK Cloudz platform.

Chris holds both a PhD and BS in Biomedical/Medical Engineering from Rensselaer Polytechnic Institute.

Tucker Folsom

Tucker Folsom is an R&D Associate Scientist at PanTher Therapeutics. He is a chemist with a background including covalent immobilization of molecular catalysts on polymer backbones, residue-specific peptide modification and analytical reaction monitoring. 

Prior to joining PanTher Therapeutics, Tucker was a Chemist at Erisyon where he designed peptide modification and chemical linker strategies used for Single Molecule Protein Sequencing via fluorosequencing. 

Tucker holds a BS in Chemistry from Texas A&M University and took graduate level coursework in Chemistry at California Institute of Technology.